Shiyang Weng , Huichao Fu , Shengxiang Xu , Jieruo Li
{"title":"基于网络药理学和信息学的整合,验证骨质疏松症治疗的核心治疗靶点。","authors":"Shiyang Weng , Huichao Fu , Shengxiang Xu , Jieruo Li","doi":"10.1016/j.slast.2024.100122","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>Our goal was to find metabolism-related lncRNAs that were associated with osteoporosis (OP) and construct a model for predicting OP progression using these lncRNAs.</p></div><div><h3>Methods</h3><p>The GEO database was employed to obtain gene expression profiles. The WGCNA technique and differential expression analysis were used to identify hypoxia-related lncRNAs. A Lasso regression model was applied to select 25 hypoxia-related genes, from which a classification model was created. Its robust classification performance was confirmed with an area under the ROC curve close to 1, as verified on the validation set. Concurrently, we constructed a ceRNA network based on these genes to unveil potential regulatory processes. Biologically active compounds of STZYD were identified using the Traditional Chinese Medicine System Pharmacology Database and Analysis Platform (TCMSP) database. BATMAN was used to identify its targets, and we obtained OP-related genes from Malacards and DisGeNET, followed by identifying intersection genes with metabolism-related genes. A pharmacological network was then constructed based on the intersecting genes. The pharmacological network was further integrated with the ceRNA network, resulting in the creation of a comprehensive network that encompasses herb-active components, pathways, lncRNAs, miRNAs, and targets. Expression levels of hypoxia-related lncRNAs in mononuclear cells isolated from peripheral blood of OP and normal patients were subsequently validated using quantitative real-time PCR (qRT-PCR). Protein levels of RUNX2 were determined through a western blot assay.</p></div><div><h3>Results</h3><p>CBFB, GLO1, NFKB2 and PIK3CA were identified as central therapeutic targets, and ADD3-AS1, DTX2P1-UPK3BP1-PMS2P11, TTTY1B, ZNNT1 and LINC00623 were identified as core lncRNAs.</p></div><div><h3>Conclusions</h3><p>Our work uncovers a possible therapeutic mechanism for STZYD, providing a potential therapeutic target for OP. In addition, a prediction model of metabolism-related lncRNAs of OP progression was constructed to provide a reference for the diagnosis of OP patients.</p></div>","PeriodicalId":54248,"journal":{"name":"SLAS Technology","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2472630324000049/pdfft?md5=24a96fd12ebc75cda35f785cd7116377&pid=1-s2.0-S2472630324000049-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Validating core therapeutic targets for osteoporosis treatment based on integrating network pharmacology and informatics\",\"authors\":\"Shiyang Weng , Huichao Fu , Shengxiang Xu , Jieruo Li\",\"doi\":\"10.1016/j.slast.2024.100122\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p>Our goal was to find metabolism-related lncRNAs that were associated with osteoporosis (OP) and construct a model for predicting OP progression using these lncRNAs.</p></div><div><h3>Methods</h3><p>The GEO database was employed to obtain gene expression profiles. The WGCNA technique and differential expression analysis were used to identify hypoxia-related lncRNAs. A Lasso regression model was applied to select 25 hypoxia-related genes, from which a classification model was created. Its robust classification performance was confirmed with an area under the ROC curve close to 1, as verified on the validation set. Concurrently, we constructed a ceRNA network based on these genes to unveil potential regulatory processes. Biologically active compounds of STZYD were identified using the Traditional Chinese Medicine System Pharmacology Database and Analysis Platform (TCMSP) database. BATMAN was used to identify its targets, and we obtained OP-related genes from Malacards and DisGeNET, followed by identifying intersection genes with metabolism-related genes. A pharmacological network was then constructed based on the intersecting genes. The pharmacological network was further integrated with the ceRNA network, resulting in the creation of a comprehensive network that encompasses herb-active components, pathways, lncRNAs, miRNAs, and targets. Expression levels of hypoxia-related lncRNAs in mononuclear cells isolated from peripheral blood of OP and normal patients were subsequently validated using quantitative real-time PCR (qRT-PCR). Protein levels of RUNX2 were determined through a western blot assay.</p></div><div><h3>Results</h3><p>CBFB, GLO1, NFKB2 and PIK3CA were identified as central therapeutic targets, and ADD3-AS1, DTX2P1-UPK3BP1-PMS2P11, TTTY1B, ZNNT1 and LINC00623 were identified as core lncRNAs.</p></div><div><h3>Conclusions</h3><p>Our work uncovers a possible therapeutic mechanism for STZYD, providing a potential therapeutic target for OP. In addition, a prediction model of metabolism-related lncRNAs of OP progression was constructed to provide a reference for the diagnosis of OP patients.</p></div>\",\"PeriodicalId\":54248,\"journal\":{\"name\":\"SLAS Technology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-02-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2472630324000049/pdfft?md5=24a96fd12ebc75cda35f785cd7116377&pid=1-s2.0-S2472630324000049-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"SLAS Technology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2472630324000049\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"BIOCHEMICAL RESEARCH METHODS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"SLAS Technology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2472630324000049","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0
摘要
目的:我们的目标是找到与骨质疏松症(OP)相关的代谢相关lncRNA,并利用这些lncRNA构建预测OP进展的模型:我们的目标是找到与骨质疏松症(OP)相关的新陈代谢相关lncRNA,并利用这些lncRNA构建一个预测OP进展的模型:方法:利用GEO数据库获取基因表达谱。方法:采用GEO数据库获取基因表达谱,利用WGCNA技术和差异表达分析鉴定缺氧相关lncRNA。应用 Lasso 回归模型筛选出 25 个缺氧相关基因,并从中创建了一个分类模型。其稳健的分类性能在验证集上得到了证实,ROC曲线下面积接近1。同时,我们根据这些基因构建了一个 ceRNA 网络,以揭示潜在的调控过程。利用中药系统药理数据库和分析平台(TCMSP)数据库鉴定了STZYD的生物活性化合物。我们使用 BATMAN 来确定其靶点,并从 Malacards 和 DisGeNET 中获得 OP 相关基因,然后确定与代谢相关基因的交叉基因。然后根据交叉基因构建药理学网络。药理学网络与 ceRNA 网络进一步整合,从而建立了一个包含草药活性成分、通路、lncRNA、miRNA 和靶标的综合网络。随后,利用定量实时 PCR(qRT-PCR)技术验证了从 OP 和正常患者外周血中分离的单核细胞中缺氧相关 lncRNA 的表达水平。结果:CBFB、GLO1、NFKB2和PIK3CA被确定为核心治疗靶点,ADD3-AS1、DTX2P1-UPK3BP1-PMS2P11、TTTY1B、ZNNT1和LINC00623被确定为核心lncRNAs:我们的研究发现了STZYD可能的治疗机制,为OP提供了潜在的治疗靶点。结论:我们的研究发现了STZYD可能的治疗机制,为OP提供了潜在的治疗靶点,并构建了OP进展代谢相关lncRNAs的预测模型,为OP患者的诊断提供了参考。
Validating core therapeutic targets for osteoporosis treatment based on integrating network pharmacology and informatics
Objective
Our goal was to find metabolism-related lncRNAs that were associated with osteoporosis (OP) and construct a model for predicting OP progression using these lncRNAs.
Methods
The GEO database was employed to obtain gene expression profiles. The WGCNA technique and differential expression analysis were used to identify hypoxia-related lncRNAs. A Lasso regression model was applied to select 25 hypoxia-related genes, from which a classification model was created. Its robust classification performance was confirmed with an area under the ROC curve close to 1, as verified on the validation set. Concurrently, we constructed a ceRNA network based on these genes to unveil potential regulatory processes. Biologically active compounds of STZYD were identified using the Traditional Chinese Medicine System Pharmacology Database and Analysis Platform (TCMSP) database. BATMAN was used to identify its targets, and we obtained OP-related genes from Malacards and DisGeNET, followed by identifying intersection genes with metabolism-related genes. A pharmacological network was then constructed based on the intersecting genes. The pharmacological network was further integrated with the ceRNA network, resulting in the creation of a comprehensive network that encompasses herb-active components, pathways, lncRNAs, miRNAs, and targets. Expression levels of hypoxia-related lncRNAs in mononuclear cells isolated from peripheral blood of OP and normal patients were subsequently validated using quantitative real-time PCR (qRT-PCR). Protein levels of RUNX2 were determined through a western blot assay.
Results
CBFB, GLO1, NFKB2 and PIK3CA were identified as central therapeutic targets, and ADD3-AS1, DTX2P1-UPK3BP1-PMS2P11, TTTY1B, ZNNT1 and LINC00623 were identified as core lncRNAs.
Conclusions
Our work uncovers a possible therapeutic mechanism for STZYD, providing a potential therapeutic target for OP. In addition, a prediction model of metabolism-related lncRNAs of OP progression was constructed to provide a reference for the diagnosis of OP patients.
期刊介绍:
SLAS Technology emphasizes scientific and technical advances that enable and improve life sciences research and development; drug-delivery; diagnostics; biomedical and molecular imaging; and personalized and precision medicine. This includes high-throughput and other laboratory automation technologies; micro/nanotechnologies; analytical, separation and quantitative techniques; synthetic chemistry and biology; informatics (data analysis, statistics, bio, genomic and chemoinformatics); and more.